+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 6Months - 11Months
All Genders
Healthy Volunteers
ID07505823

Evaluation of Group ACYW135 Meningococcal Conjugate Vaccine Immune Response and Safety in Healthy Children 6 to 11 Months Old

Led by Sinovac Biotech Co., Ltd · Updated on 2026-08-10

1040

Participants Needed

2

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the immune response, safety, and duration of protection of a new group ACYW135 meningococcal conjugate vaccine in healthy children aged 6 to 11 months. This phase 3 trial aims to see if the immune response from the investigational vaccine is not worse than that from a licensed control vaccine after the primary immunization series. It also assesses safety during the initial doses and a booster given at 18 months, as well as how long the immune response lasts. Participants are randomly assigned to receive either two doses of the investigational vaccine or two doses of the licensed control vaccine one month apart during the primary phase. Only those receiving the investigational vaccine will get a booster dose at 18 months of age. Blood samples are collected before vaccination, 30 days after the primary doses, at 18 months, and for the investigational group, also 30 days after the booster to measure immune response. Safety is monitored closely after each dose through observation, diary records of adverse events, and follow-up for serious reactions for at least six months after the last dose. Participants will be observed for immediate reactions for 30 minutes after each vaccination and keep diaries to record local and systemic side effects for one week, as well as any other adverse events for 30 days. Serious adverse events are followed for at least six months. The study measures the rate of antibody response to meningococcal serogroups A, C, Y, and W135 as the main outcome, along with antibody levels and persistence. The total participation period extends up to at least 18 months of age, with careful monitoring throughout.

CONDITIONS

Brief Title

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months

Research Team

Y

Yi Mo

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here